We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+33.33%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.76B
AUM Growth
+$349M
Cap. Flow
+$63.3M
Cap. Flow %
3.6%
Top 10 Hldgs %
46.56%
Holding
242
New
48
Increased
31
Reduced
35
Closed
71

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$45.5M
2
RDUS
Radius Health, Inc.
RDUS
+$27.1M
3
EVH icon
Evolent Health
EVH
+$21.8M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$20.9M
5
ANAB icon
AnaptysBio
ANAB
+$20.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$72.8M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$39.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$30.9M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$23.3M
5
ACOR
Acorda Therapeutics
ACOR
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Miscellaneous 1.35%
3 Consumer Staples 0.26%
4 Consumer Discretionary 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LHCG
126
DELISTED
LHC Group LLC
LHCG
$256K 0.01%
4,745
– –
GRCE
127
Grace Therapeutics
GRCE
$46.9M
$254K 0.01%
3,887
– –
ONSIZ
128
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$231K 0.01%
462,500
-193,882
-30% -$83.9K
ARRY
129
DELISTED
Array Biopharma Inc
ARRY
$228K 0.01%
+25,510
New +$271K
EVH icon
130
CALL
Evolent Health
EVH
$423M
$190K 0.01%
+50,000
New +$960K
BOLD
131
DELISTED
Audentes Therapeutics, Inc
BOLD
$128K 0.01%
7,500
– –
RXDX
132
DELISTED
Ignyta, Inc.
RXDX
$57K ﹤0.01%
6,584
– –
RCM
133
DELISTED
R1 RCM Inc. Common Stock
RCM
$56K ﹤0.01%
+17,976
New +$51.4K
SYRE icon
134
Spyre Therapeutics
SYRE
$8.02B
$43K ﹤0.01%
233
-3,910
-94% -$552K
ABBV icon
135
AbbVie
ABBV
$465B
$25K ﹤0.01%
+380
New +$23.9K
CLDX icon
136
Celldex Therapeutics
CLDX
$3.02B
$25K ﹤0.01%
+465
New +$24.2K
CBPO
137
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$24K ﹤0.01%
236
– –
BMRN icon
138
BioMarin Pharmaceuticals
BMRN
$12.5B
$22K ﹤0.01%
250
– –
EPZM
139
DELISTED
Epizyme, Inc
EPZM
$20K ﹤0.01%
+1,165
New +$15.5K
ABT icon
140
Abbott
ABT
$177B
$18K ﹤0.01%
415
-49,585
-99% -$2.14M
CDMO
141
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$16K ﹤0.01%
3,476
– –
AGEN
142
Agenus
AGEN
$322M
$14K ﹤0.01%
183
-3,495
-95% -$277K
CAPR icon
143
Capricor Therapeutics
CAPR
$498M
$13K ﹤0.01%
400
– –
WST icon
144
West Pharmaceutical
WST
$25.7B
$11K ﹤0.01%
138
– –
ARCT icon
145
Arcturus Therapeutics
ARCT
$450M
$10K ﹤0.01%
+1,301
New +$12K
TXMD icon
146
TherapeuticsMD
TXMD
$25M
$8K ﹤0.01%
22
-5,978
-100% -$1.85M
CASC
147
DELISTED
Cascadian Therapeutics, Inc.
CASC
$8K ﹤0.01%
1,966
-544,532
-100% -$2.29M
ISEE
148
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5K ﹤0.01%
+1,600
New +$6.76K
FPRX
149
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$5K ﹤0.01%
127
-163,128
-100% -$7.19M
CERS icon
150
Cerus
CERS
$504M
$3K ﹤0.01%
+740
New +$3.14K
4 5
6
7 8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Perceptive Advisors held 242 positions worth $1.76B, up 25% from $1.41B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $63.3M of net new capital in Q1 2017, opening 48 new positions and adding to 31 existing holdings. Its largest new stake was AnaptysBio: 881,957 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was TESARO, Inc., an estimated $72.8M trimmed.

  • Perceptive Advisors's largest Q1 2017 buy was AnaptysBio: 881,957 shares worth $24.5M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q1 2017, an estimated $45.5M increase.
  • Perceptive Advisors's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $72.8M.
  • Perceptive Advisors fully exited Eagle Pharmaceuticals, Inc. in Q1 2017, selling an estimated $39.5M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.76B portfolio in Q1 2017.
  • Perceptive Advisors opened 48 new positions and closed 71 in Q1 2017.
  • Perceptive Advisors's portfolio value rose 25% quarter-over-quarter to $1.76B.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.